Ironwood Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IRWD)

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings results on Tuesday, July, 30th. The biotechnology company reported $0.08 EPS for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.15. The biotechnology company earned $102.22 million during the quarter, compared to the consensus estimate of $89.28 million. The company's revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.22) EPS. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals updated its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $370-390 million, compared to the consensus revenue estimate of $374.63 million.

11 equities research analysts have issued 12-month target prices for Ironwood Pharmaceuticals' stock. Their predictions range from $12.00 to $20.00. On average, they expect Ironwood Pharmaceuticals' stock price to reach $15.05 in the next year. This suggests a possible upside of 66.4% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

Media stories about IRWD stock have trended somewhat negative recently, according to InfoTrie. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ironwood Pharmaceuticals earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Ironwood Pharmaceuticals.

Some companies that are related to Ironwood Pharmaceuticals include Amarin (AMRN), Horizon Therapeutics (HZNP), The Medicines (MDCO), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), United Therapeutics (UTHR), Blueprint Medicines (BPMC), Mirati Therapeutics (MRTX), FibroGen (FGEN), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Allakos (ALLK), Reata Pharmaceuticals (RETA), Global Blood Therapeutics (GBT) and Alkermes (ALKS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Allergan (AGN) and Continental Resources (CLR).

Ironwood Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.81%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $9.05.

Ironwood Pharmaceuticals has a market capitalization of $1.42 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.View Additional Information About Ironwood Pharmaceuticals.

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com/.

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]